Penumbra, Inc. PEN | NYSE

$242.54 -$0.98 | -0.40%

After Hours
$238.93 -$3.61 | -1.49%

Company Overview:

Market Cap: $9.31B
PE Ratio: 275.61
52-Week Range: $148 - $277.34
Dividend Yield (FWD): 0.00% ($0.00)

5.9 Year Performance Metrics:

Total Return (with DRIP): 66.68% (9.05% / yr)
Total Return (no DRIP): 66.68% (9.05% / yr)
Share Price: 66.68%
Dividend Increase: nan%
PEN 5.9-yr Total Return ($10,000 investment)
1Y 2Y 5Y 10Y All

PEN Dividend Payments, Yield & Share Price charts

Dividend Payments & Yield
PEN Dividend CAGR:1Y: N/A2Y: N/A5Y: N/A10Y: N/A
Share Price
PEN Price CAGR:1Y: -1.81%2Y: 4.97%5Y: 8.72%10Y: 5.24%

Unlock All Reports & Research Dividend Stocks like a BOSS!

Monthly
$15/mo
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 33% OFF
$120/yr
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial

PEN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.

Dividend payout ration is Dividend/EPS, and indicates if company can afford to pay dividends from net income that it earned in the quarter.

Since EPS can be played with using different "accounting gymnastics", a better measure of dividends safety is Dividend to Free Cash Flow (FCF) ratio.

FCF is how much cash the company has earned each quarter, after paying all expenses not related to earnings.

Lower Ratio indicates SAFER Dividend! Ratios consistently close to, or over 100% are usually unsustainable and often indicate a dividend cut might be coming soon.

Dividend Payout Ratio - PEN
14-Day FREE Trial Get Full Access Now!
Dividend to Free Cash Flow Ratio - PEN
14-Day FREE Trial Get Full Access Now!

PEN Earnings, Revenue, Cash & Debt, Shares Outstaning:

PEN - EPS vs PE Ratio
14-Day FREE Trial Get Full Access Now!
PEN - FCF vs FCF / Share
14-Day FREE Trial Get Full Access Now!
PEN - EPS vs FCF / Share
14-Day FREE Trial Get Full Access Now!
PEN - FCF vs Stock Based Comp
14-Day FREE Trial Get Full Access Now!
PEN - Revenue vs Net Income
14-Day FREE Trial Get Full Access Now!
PEN - Cash & Debt
14-Day FREE Trial Get Full Access Now!
PEN - Revenue
14-Day FREE Trial Get Full Access Now!
PEN Revenue CAGR:1Y: 11.11%2Y: 18.69%5Y: 16.63%10Y: 24.95%
PEN - Earnings Per Share (EPS)
14-Day FREE Trial Get Full Access Now!
PEN EPS CAGR:1Y: 226.09%2Y: 281.06%5Y: 18.57%10Y: 59.59%
PEN - Net Income
14-Day FREE Trial Get Full Access Now!
PEN Net Income CAGR:1Y: 220.46%2Y: 287.32%5Y: 20.79%10Y: 67.29%
PEN - EBITDA
14-Day FREE Trial Get Full Access Now!
PEN EBITDA CAGR:1Y: -20.94%2Y: 94.84%5Y: 24.11%10Y: 56.48%
PEN - Free Cash Flow
14-Day FREE Trial Get Full Access Now!
PEN Free Cash Flow CAGR:1Y: 85.43%2Y: 115.62%5Y: 29.27%10Y: 30.98%
PEN - Free Cash Flow / Share
14-Day FREE Trial Get Full Access Now!
PEN Free Cash Flow / Share CAGR:1Y: 84.72%2Y: 114.41%5Y: 26.64%10Y: 26.10%
PEN - Gross Profit
14-Day FREE Trial Get Full Access Now!
PEN Gross Profit CAGR:1Y: 12.71%2Y: 21.66%5Y: 15.85%10Y: 25.42%
PEN - Expenses
14-Day FREE Trial Get Full Access Now!
PEN Expenses CAGR:1Y: 63.60%2Y: -7.33%5Y: -7.19%10Y: 18.72%
PEN - Shares Outstanding
14-Day FREE Trial Get Full Access Now!
PEN Shares Outstanding CAGR:1Y: -0.11%2Y: 1.65%5Y: 1.55%10Y: 4.80%
PEN - Share Buybacks
14-Day FREE Trial Get Full Access Now!
PEN Share Buybacks CAGR:1Y: 81,101.63%2Y: 627.53%5Y: N/A10Y: 28.01%
PEN - Stock-Based Comp
14-Day FREE Trial Get Full Access Now!
PEN Stock-Based Comp CAGR:1Y: -22.61%2Y: 6.19%5Y: 11.88%10Y: 40.23%
PEN - Dividends
14-Day FREE Trial Get Full Access Now!
PEN Dividend CAGR:1Y: N/A2Y: N/A5Y: N/A10Y: N/A
PEN - Revenue by Segment
14-Day FREE Trial Get Full Access Now!
PEN Revenue CAGR:1Y: 11.11%2Y: 18.69%5Y: 16.63%10Y: 24.95%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

PEN - REVENUE: Actual + Estimates
14-Day FREE Trial Get Full Access Now!
PEN Actual Revenue CAGR:1Y: 11.11%2Y: 18.69%5Y: 16.63%10Y: 24.95%
PEN - EPS: Actual + Estimates
14-Day FREE Trial Get Full Access Now!
PEN Actual EPS CAGR:1Y: 226.09%2Y: 281.06%5Y: 18.57%10Y: 59.59%
PEN - NET INCOME: Actual + Estimates
14-Day FREE Trial Get Full Access Now!
PEN Actual Net Income CAGR:1Y: 220.46%2Y: 287.32%5Y: 20.79%10Y: 67.29%
PEN - EBITDA: Actual + Estimates
14-Day FREE Trial Get Full Access Now!
PEN Actual EBITDA CAGR:1Y: -20.94%2Y: 94.84%5Y: 24.11%10Y: 56.48%

Ratios, Profit Margins & Return on Capital:

PEN - Net Profit Margin
14-Day FREE Trial Get Full Access Now!
PEN Net Profit Margin CAGR:1Y: 188.53%2Y: 235.48%5Y: 3.57%10Y: 33.89%
PEN - Gross Profit Margin
14-Day FREE Trial Get Full Access Now!
PEN Gross Profit Margin CAGR:1Y: 1.45%2Y: 2.50%5Y: -0.67%10Y: 0.38%
PEN - Price to Earnings
14-Day FREE Trial Get Full Access Now!
PEN - Price To Sales Ratio
14-Day FREE Trial Get Full Access Now!
PEN - Return on Capital Employed
14-Day FREE Trial Get Full Access Now!
PEN - Return on Invested Capital
14-Day FREE Trial Get Full Access Now!

Compare stocks side-by-side
 

PEN Dividends Info:

Annual Dividend: $
Forward Yield: 0%
Ex-Dividend Date:
Lifetime Dividens / Share: $0.00

PEN Dividend History: Dates, Payments & Yield list

Below is a schedule of all PEN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield

Ex-Date Payment Date Amount TTM Yield Forward Yield Price on Ex-Date

Get the best Dividend Stock Research Tools:

Monthly
$15/mo
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 33% OFF
$120/yr
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial

Projected Future Returns & Dividends for PEN

Based on past 5.9-year performance, here are PEN growth metrics:

Share price CAGR of +8.72%
Dividend CAGR of +0%
Using PEN CAGR metrics, we can estimate, that your initial $10000 investment, over next 10 years ago, should grow with dividends being reinvested (DRIP) as follows:

PEN
Current Price$242.54
Start Shares41.23
Start Value$10,000
 
After 10 years:
Final Share Count41.23
Dividends Payment$0.00
Annual Dividends$0
Yield on cost0.00%
Share Price$514.69
Total Dividends$0
Final Value$21,221

Estimated Future Value + Dividends - PEN

NOTE: Above numbers are our estimate based on PEN's Dividend and Price CAGR over past 5.9 years. These numebrs should only be considered as "potential future returns"! These numbers assume DRIP (reinvesting dividends).

We cannot guarantee that your actual returns will meet these estimates.

Company Info

Penumbra, Inc. (PEN) had its IPO on 2015-09-18, and is trader on NYSE stock exchange.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN website: https://www.penumbrainc.com


Get Full Access to All Reports with DRIPCalc PRO

Monthly
$15/mo
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 33% OFF
$120/yr
14-days Free Trial.
Unlimited Access to dividend stocks reports & multiple metrics, for Dividend-oriented Investors.
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial